GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D

Company

Addex Therapeutics Ltd.

Filed

January 22, 2021

Accession Number

0001072613-21-000050

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →